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A bstract
Although robot-assisted coronary artery bypass grafting (RA-CABG) has gained 
more acceptance worldwide, its success still depends on the surgeon’s experience and 
expertise, and the conversion rate to full sternotomy is in the order of 15% — 25%. One 
of the reasons for conversion is poor pre-operative planning, which is based solely on 
pre-operative computed tomography (CT) images. This thesis proposes a technique 
to estimate the global peri-operative displacement of the heart and to predict the 
intra-operative target vessel location. The technique has been validated via both 
an in vitro and a clinical study, and predicted the position of the peri-operative 
target vessel location with ~  3.5 mm RMS accuracy in the in vitro study while it 
yielded ~  5.0 mm accuracy for the clinical validation. As the desired clinical accuracy 
imposed by this procedure is on the order of one intercostal space (10 - 15 mm), our 
technique suits the clinical requirements. It is therefore believed that this technique 
has the potential to improve the pre-operative planning by updating peri-operative 
migration patterns of the heart and, consequently, will lead to reduced conversion to 
conventional open thoracic procedures.
Key words: Image-guided cardiac surgery, Minimally invasive surgery, CABG, rigid- 
body registration, ultrasound, phantom study
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1.1 Coronary A rtery D isease
Coronary artery disease (CAD) is one of the most common diseases worldwide. 
In North America, CAD is the leading cause of death. For example, 44% of the 
mortality and much of the morbidity in the United States is attributed to CAD [1]. 
The average life expectancy would increase by almost 7 years if all forms of CAD 
were to be eliminated [2]. The costs related to cardiac disease is very high according 
to the 2010 National Heart, Lung and Blood Institute which reported that CAD 
costs patients $155.7 billion for medical care and $503.2 billion in direct and indirect 
economic costs [3].
Except for a small number of patients, CAD is caused by a condition called 
atherosclerosis, which occurs when fatty plaques or other substances are formed on 
the walls of arteries and restrict normal blood flow. Since fatty plaques can be caused 
by many different factors, there is no single cause of CAD. However, clinicians and 
scientists have developed a set of “risk factors” that are measurable characteristics 
that predict the probability of developing CAD. The next section will review some of 
the risk factors which predispose to developing CAD.
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1.1.1 R isk Factors
1.1.1.1 Lipoproteins
It has been established that low-density Lipoprotein (LDL) and high-density 
Lipoprotein (HDL) cholesterol is closely linked to CAD. Increased LDL cholesterol 
concentration increases the risk of CAD [4-6], while reduced HDL is also an indicator 
of CAD [4, 7, 8]. Although the role of LDL has not been fully determined, most 
researchers believe that its major role is in the formation of blood clots.
1.1.1.2 Blood Pressure
Blood pressure in patients is also an important factor in developing CAD. Mas­
ter et al. have reported that patients who have increased blood pressure were more 
susceptible to developing CAD and having a stroke [9]. Moreover, hypertension is as­
sociated with insulin resistance, which may increase the risk of atherosclerosis through 
other mechanisms [10].
1.1.1.3 Smoking
In a 2010 report, the latest from the U.S. Department of Health and Human 
Services, the Surgeon General confirmed that smoking was an independent risk factor 
for CAD [11]. Although it is not known exactly how tobacco increases the risk, one 
of the effects of smoking is the acceleration of atherogenesis, which is the formation 
of atherosclerosis. This indicated an increased risk for clinically manifested CAD.
1.1.1.4 Male sex
Being a male is one of the highest risk factors for CAD [12]. In the United States, 
one in every three men younger than 60 develops CAD, in contrast to only one in 
10 for women [1]. Although middle aged males have a higher risk of CAD, this risk
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increases for post-menopausal women and the rate is eventually identical for both 
sexes who are older than 60.
1.1.1.5 Diabetes
Beckman et al. [13] reported that patients with diabetes have a higher risk of 
developing CAD. Many patients who have diabetes develop insulin resistance and 
insulin resistance is found to be associated with decreased HDL cholesterol, increased 
LDL cholesterol, as well as increased blood pressure [14].
1.1.2 Sym ptom s
Symptoms of CAD can vary from totally asymptomatic to fatal. However, the 
most common symptom is chest pain or discomfort (angina). As atherosclerosis blocks 
normal blood flow in the arteries, the lack of oxygen to the heart tissue, commonly 
expressed as angina, is the result. Possible symptoms other than angina encompass 
shortness of breath, fatigue during activity, acute coronary syndrome (ACS) or sudden 
cardiac death. Patients with ACS are at high risk of cardiac muscle cell death in the 
immediate future. Possible outcomes of cardiac muscle cell death are unstable angina 
and myocardial infarction (MI).
1.2 Treatm ent O ptions For C A D
Below, we consider some treatment options for CAD.
1.2.1 M edication
Medication is a common option to prevent or reduce the further development in 
the early stages of CAD. Although many factors contribute to the progression of CAD, 
there are several biomarkers which indicate the severity of the disease. For example,
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elevation of Myeloperoxidase (MPO) and LDL, and reduction of HDL are strong 
indicator of the atherosclerosis. The following section will explain the three different 
types of drugs which are commonly used to treat CAD : statins, beta-blockers, and 
antiplatelet drugs.
1.2.1.1 Statins
Statins is the common name for the group of HMG-CoA reductase inhibitors used 
to control HDL and LDL. As the literature reported, the development of CAD is 
closely related to the level of LDL in the blood stream [15]. Statins work by inhibit­
ing an enzyme called HMG-CoA reductase, which is responsible for producing LDL. 
Among different cholesterol controlling drugs, statins have proven effective in reducing 
cardiovascular morbidity and mortality in both primary and secondary prevention. 
The role of primary prevention is to decrease the rate of heart attacks and strokes 
for those who have not had any known cardiovascular diseases. Secondary prevention 
refers to treatment administered to patients with pre-existing cardiovascular disease.
Waters et al [16] conducted the Canadian Coronary Atherosclerosis Intervention 
Trial (CCAIT) and concluded that patients who have received Lovastatin (one of 
the statins) experienced less progression of CAD compared with those who were 
treated with a placebo. Another trial, Monitored Atherosclerosis Regression Study 
(MARS), was also consistent with the reports from CCAIT [17]. Pravastatin, a 
second statin, has also been shown to reduce the level of LDL. The Pravastatin 
Limitation of Atherosclerosis in the Coronary arteries study showed that patients 
who were treated with Pravastatin had a 40% reduction in LDL cholesterol level 
and progression of atherosclerosis, compared with the control group who received 
placebo [18]. Statins also have shown its effectiveness on MPO, which is an enzyme 
that promotes atherosclerosis and acute coronary syndromes, with Ndrepepa et al [19] 
reporting that the use of statins lowered the level of MPO by 20% compared to 
patients without statin therapy.
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Statins have been proven to reduce the risk of atherosclerosis through other means 
other than controlling cholesterol levels. For example, Bellosta et al reported that 
the use of statins can inhibit smooth muscle cell growth. Thus, these agent may 
slow the progression of atherosclerosis [20]. In addition, Rosenson et al showed that 
statins promote plaque stability through a combination of its lipid-lowering properties 
and inhibitory effects on macrophage activation that consequently reduces the risk of 
plaque rupture [21].
1.2.1.2 Antiplatelet Drug
As platelets are believed to play an important role both in the pathogenesis of 
atherosclerosis and in the development of coronary thrombosis, antiplatelet drugs, 
which inhibit the activity of platelets, are typically used on patients who have CAD, 
with well proven benefits.
Antiplatelet drugs were first introduced to treat CAD in 1953 for protective pur­
poses. Although there are many different antiplatelet drugs, aspirin and clopidogrel 
are the ones which have been widely studied and most commonly used. The benefit 
of aspirin was first reported in 1763, but in order to make this drug applicable for 
CAD, it took much more time and it only recently became a therapy in CAD. The 
use of aspirin was researched both for primary and secondary prevention. Research 
on aspirin for secondary prevention is well studied and shows positive results in that 
it improves clinical outcomes in patients with ACS, coronary artery bypass grafting 
(CABG), and percutaneous coronary intervention (PCI) even though there is a risk 
of bleeding. The Antiplatelet Trialists’ Collaboration conducted a study involving 
135000 patients, with the following results: any serious vascular mortality was re­
duced by 25%, non-fatal myocardial infraction by 30%, non-fat al stroke by 25% and 
vascular mortality by 15% [22]. Moreover, the Canadian Antiplatelet Therapy Guide­
line recommends a low dose of aspirin for patients who have undergone ACS, CABG, 
PCI and cerebrocascular disease [23]. For primary prevention, however, the effective-
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ness of antiplatelet drugs does not appear to be consistent, as some studies showed 
the improvement of the outcomes [24] while other studies stated otherwise [25]. Gen­
erally speaking, even with the benefits, there is major risk of bleeding from treatment 
with antiplatelet drugs. Therefore, benefits are rather nullified or diminished and 
other types of therapy are recommended.
Lastly, recent studies found that patients who have been treated with antiplatelet 
drugs for long time do not respond to them and such situations have been termed “as­
pirin or clopidogrel resistance”. This phenomenon could put patients in a dangerous 
situation as Gum et al. [26] reported. Patients who have a resistance to aspirin have 
a higher risk of myocardial infraction and death, compared with aspirin responders. 
Therefore, even with the benefits of antiplatelet drugs, its use should be carefully 
monitored.
1.2.1.3 /3-adrenergic blockers
/3-adrenergic blockers are so named as they inhibit /3-adrenergic receptors of 
epinepherine and norepinipherine on the sympathetic nervous system, which are re­
sponsible for increasing heart rate and vasocontraction. Since the /3-adrenergic blocker 
was clinically introduced in 1962, it has been used for treating CAD and hypertension.
/3-adrenergic blockers have been used as the first-line therapy for hypertension 
and its related diseases. For example, /3-adrenergic blockers significantly reduced 
the risk of developing a stroke when compared with a placebo. Also, the patients 
who were treated with /3-adrenergic blockers showed a 20% lower risk of having a 
cardiovascular event compared to those on a placebo [27]. As a treatment for CAD, 
/3-adrenergic blockers are typically used for secondary prevention rather than primary 
prevention. Hawkins et al. [28] reported up to a 34% reduction in mortality with the 
use of /3-adrenergic blockers to those patients who have had previous MI. Moreover, 
sudden cardiac death was also reduced by up to 16% in patients who were taking /3- 
adrenergic blockers compared to those on a placebo [29]. With these positive clinical
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outcomes, ACC/AHA guidelines recommend that patients who have had MI take 
/3-blocker therapy unless patients show a clear contraindication to the therapy [30].
The main limitation of /3-adrenergic blockers is, however, that its effectiveness on 
primary prevention is still not clear. Moreover, like other types of medication, the 
use of /3-adrenergic blockers is limited to preventing the progress of the disease and 
to relieving the pain instead of curing the disease. These limitations force patients 
who have severe CAD to undergo other types of treatment such as an intravascular 
therapy or surgery.
1.2.2 Intravascular T herapy
Intravascular therapy is a non-surgical revascularization treatment for CAD which 
uses a catheter to perform arterial dilation at the site of atherosclerosis. There are 
two different types of PCI procedure dependent on how arterial dilation is performed: 
i.e. with a balloon and stent. Balloon angioplasty was invented before stent angio­
plasty and uses a balloon, which is placed in a catheter, to be inflated at the site 
of atherosclerosis. On the other hand, a stent deployment leaves a metal frame to 
support the arterial wall following inflation of the target vessel.
1.2.2.1 Percutaneous Transluminal Coronary Angioplasty
Percutaneous Transluminal Coronary Angioplasty (PTCA) was first performed on 
coronary arteries in 1977 by Dr. Andreas Gruentzig [31]. After the success of the first 
PTCA, it became an alternate treatment option to CABG surgery for atherosclerosis.
PTCA is a procedure used to increase the luminal size of the artery where blood 
flow has been disrupted by atherosclerotic plaque, so that the normal blood flow can 
be restored. For a typical PTCA procedure, a guide catheter containing a flexible 
guide wire, a balloon catheter and contrast enhancing material for visualization, is 
inserted into the femoral artery. Under fluoroscopic guidance, the guide catheter
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advances to the ostium of the coronary artery to be dilated. Once the guide catheter 
reaches its destination, the guide wire continues to advance to the stenosis and is 
positioned in the distal arterial segment. The deflated balloon catheter then travels 
through the wire and is positioned across the stenosis. The location of the guide wire 
and the deflated balloon catheter is frequently confirmed by fluoroscopy with the aid 
of intravascular contrast injected via the guide catheter. Once the location of the 
deflated balloon catheter is confirmed, the balloon is inflated at a constant pressure 
(usually 6 to 8 atmospheres). If the dilation of the stenosis is adequate in the view of 
the surgeon, the guide catheter including the guide wire and the balloon catheter are 
removed. If the desired dilation is not reached, the balloon catheter may be replaced 
with one of larger diameter, while the guide wire continues to be held across the 
stenosis.
Prom an efficacy point of view, about 90 percent of the non-occluded coronary 
cases are performed successfully, which leads to effective relief of angina [32, 33]. 
Moreover, because of the nature of its non-invasiveness, PTCA is often considered as 
an alternative treatment option for patients with recurrent angina who have under­
gone CABG previously. However, PTCA appears less effective when the stenoses are 
long, eccentric, or located at the ostium or the site of a branch point [34]. Patients 
with unstable angina or advanced age might also have a lowered success rate.
A small percentage of patients who undergo PTCA procedures experience com­
plications: 3% -  5% of patients have MI and 3% — 7% require emergency bypass 
surgery [35-37]. The death rate from PTCA is reported as 0% — 6% [38, 39] while 
2% — 7% of patients experience acute or abrupt closure of the artery [36, 40]. When 
the artery has a abrupt closure, an immediate revascularization (PTCA or CABG) 
is required. For long-term complications, restenosis, the state when stenosis recurs, 
frequently occurs in PTCA patients. Where the balloon dilates the lumen, damage to 
the smooth muscle cells in the media may occur, leading to immediate platelet depo­
sition or thrombus formation. Restenosis typically happens within six months after
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the procedure and the rate of restenosis can be as high as 50% [41-43]. Restenosis 
can be treated with a second PTCA treatment but the incidence of restenosis after 
the second treatment is similar to that after the first.
When compared to medical therapy, PTCA gives patients an immediate relief from 
angina and greater improvement in exercise performance [33]. However, compared to 
medical therapy PTCA has a higher risk of MI and emergency bypass surgery [44]. 
Furthermore, PTCA might cause abrupt closure of the artery or restenosis. Although 
PTCA has the benefits of rapid and complete relief of angina, many patients are first 
treated with the medical therapy and proceed to PTCA or other revascularization if 
the medical therapy does not work.
1.2.2.2 Stents
Due to PTCA’s high rate of restenosis as a result of the damage to the smooth 
muscle cells or elastic recoil of the lumen, an alternative intravascular therapy is the 
stent. The principal mechanism of a stent is almost identical to PTCA. However, the 
difference between the two therapies is that stents place a metal frame after the aterial 
dilation which is left inside the patient permanently, while PTCA uses a balloon as 
an one-time therapy.
Although stents were first clinically used in 1986 [45], the use of stents began to 
replace PTCA around 1994 [46]. Since then the use of a stent have become the primary 
choice for intravascular therapy, because it reduces the risk of restenosis significantly 
(about 25% — 30%) compared to PTCA (around 50%) [47, 48]. It also reduces the risk 
of the immediate need of revascularization, such as a second intravascular therapy 
or surgery for abrupt vessel closure, since the metal frame stays inside the lumen 
permanently. However, because stents introduce foreign material into the human 
body, there is a chance the patient may develop thrombosis, the formation of a blood 
clot resulting from the presence of foreign material in the blood stream. Thrombosis 
usually leads to MI or death [49, 50]. To prevent this, patients who have undergone
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stent surgery must take an antiplatelet drug for rest of their lives. Furthermore, 
although the rate of restenosis is greatly reduced compared to PTCA, 30% is still 
high and may require repeat intravascular procedures or surgery [51]. To overcome 
these issues, researchers have tried different types of material to replace the metal 
frame, such as inorganic elements (e.g. gold) or polymer (e.g. polyactic acid and 
fibrin) [52, 53]. These attempts slightly decreased the rate of thrombosis , but the 
rate of restenosis remained as high as 25% — 30%.
Drug-Eluting Stents (DES) are an advanced type of stent, that was fully approved 
by the Food and Drug Administration (FDA) in 2003 [53]. The metal frame in 
DES is coated with an outer drug-loaded layer of polymer. This allows the right 
amount of a drug to be placed at the site of stenosis to prevent restenosis. When 
compared with bare-metal stent, DES shows improved results on the rate of restenosis. 
Moreover, the Arterial Revascularization Therapies Study (ARTS) showed that the 
rate of major adverse cardiac and cerebrocascular events (including MI, death, and 
revascularization) is significantly lower than when using a bare-metal stent (15.9% vs 
31.0%) and similar to that of CABG (16.4%) [54].
Among the many drugs which are in the trial process for their effectiveness, 
sirolimus and taxol are currently available in clinical trials for DES. The rate of 
restenosis for Sirolimus-eluting stent was as low as 2.3% compared to bare metal- 
stent which was as high as 52.3% [55, 56]. Also, the rate of major adverse cardiac 
event was reduced to 5.8%, versus 28.8%, for bare-metal stent [57]. Some literature 
reported that Taxol-eluting stent reduced the restenosis rate to 5% from 25% for the 
bare-metal stent [58, 59]. Even considering that many of these studies were conducted 
with small sample sizes, they adequately showed the effectiveness of using DES over 
the bare-metal stent.
Despite the success of DES, its chief limitation is found in repeat revascularization 
mostly due to restenosis. Although some literature claims that the rate of restenosis 
for DES is as low as 5%, the rate of repeat revascularization is still high when com-
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pared to CABG (29.0%, 7.9%) [60, 61]. DES on patients who have diabetes appears 
not to work as well as those without diabetes because the rate of stenosis and major 
adverse cardiac events are much higher than CABG [54].
Finally, when stents are compared to medical therapy, one study shows that there 
is no significant difference in the primary event rate, which includes death and MI. 
However, about one third of patients who have been treated with medical therapy 
requires revascularization due to unstable angina [62]. In conclusion, medical therapy 
is optimal for those with stable angina but if patients have severe ischemia burden or 
unstable angina, or they want to have immediate relief from their pain, stents should 
be considered.
1.3 C oronary A rtery B ypass Surgery
CABG surgery is a surgical treatment of CAD. The chief goal of CABG is to 
restore normal blood flow to the affected arteries, which were occluded by atheroscle­
rosis. CABG is a revascularization procedure, where a bypass conduits is inserted at 
the region distal to the site of the atherosclerosis to provide an alternative route for 
blood. The first successful revascularization was performed in 1957 by Bailey [63]. 
With the invention of cardiopulmonary bypass (CPB), which immobilizes the heart 
and halts its blood flow while shunting the pateint’s blood to a heart-lung machine, 
and the coronary angiography, CABG has become a safe and solid treatment option 
for those who have severe symptoms.
Due to the invasiveness of the surgery, great care must be taken when considering 
undergoing such surgery. Patients with mild lesions are not usually recommended 
for the surgery but instead are recommended other types of therapy such as medical 
therapy or percutaneous artery intervention. Patients who have stable angina or 
acute coronary syndromes are typical candidates for CABG procedure. The size of 
the target vessel should also be more than 1.5 mm in order to maintain high patency
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after surgery.
In conventional CABG, the chest of the patient is open (median sternotomy) and 
the bypass conduit is harvested. The Saphenous vein or internal thoracic artery (ITA) 
are commonly used as bypass conduits. The choice for the right conduit depends on 
the location of anastomosis and the number of bypass. For example, ITA is usually 
chosen over the saphenous vein because ITA has better patency and is free from 
repeat revascularization. Fitzgibbon [64] reported that CABG using the saphenous 
vein had 88% early vein graft patency, but decreased to 75% after 5 years and 50% 
after 15 years, which may lead to re-operation. On the other hand, many studies 
supported ITA as the choice conduit because of its long-term patency of over 90% 
after 10 years [65, 66]. However, if patients requires more than three grafts, the 
saphenous vein is usually employed after the use of both ITA (left and right).
Daement et al [60] reported that there is not much difference in the rate of 
death, stroke or MI when CABG is compared to intravascular therapy. However, 
repeat revascularization was significantly higher with stents, which could lead to a 
significantly increased risk of adverse cardiac events. The cost of intravascular therpy 
was 35% lower than that of CABG and with a better comfort level for patients 
after the procedure, compared to CABG [67]. In conclusion, the main benefits of 
intravascular therapy over CABG is the cost effectiveness of the procedure and the 
reduced length of recovery. However, in the long run, CABG provides a clinical 
freedom from repeat revascularization that intravascular therapy does not guarantee.
1.3.1 Off-pump C A B G
Although an optimal surgical condition for CABG is achieved by using CPB, the 
complications associated with the use of CPB are pulmonary, renal and neurolog­
ical dysfunction, the risk of blood loss and transfusion and myocardial injury and 
dysfunction [68, 69]. Moreover, patients with normal ventricular function generally 
tolerate the use of CPB well for prolonged periods, but it could significantly increase
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the peri-operative mortality and morbidity rates if used on patients with depressed 
ventricular function [70]. Therefore, CABG on the beating heart started to be con­
sidered something to avoid in order to prevent the adverse effects from the use of 
CPB.
CABG procedure with the beating heart is generally referred to as off-pump 
CABG (OPCAB) and typically involves median sternomy. Unlike the conventional 
CABG, however, a shorter incision is required for the OPCAB because it does not 
need access to the ascending aorta, which is needed for a CPB. Since OPCAB deals 
with beating hearts, greater experience with this type of surgery is necessary and 
patients should be carefully monitored to increase the success rate compared to a 
conventional CABG. Therefore, patients, for whom the use of CPB is a risk factor, 
are optimal candidates. Such patients include the elderly, re-operative patients, or 
those with renal or pulmonary dysfunction [71-73]. Although studies are limited with 
small sample sizes, preliminary results show that OPCAB reduces complications asso­
ciated with the use of CPB. Ascione et al [74] reported that blood loss was 1.6 times 
higher with the on-pump patients compared with the off-pump patients. Also, only 
23% of patients who underwent OPCAB needed a transfusion compared with 52% of 
patient having the on-pump procedure. The same group showed that the myocardial 
function was improved on patients with OPCAB [75]. Lastly, Plomondon et al [76] 
claimed that the off-pump mortality and complication rates decreased from 4.0% and 
14% to 2.7% and 8.8% respectively, when compared with the on-pump patients.
Although OPCAB requires a surgeon with more experience and expertise, it pro­
vides an alternative for those who could not have undergone the conventional CABG 
with good outcomes.
1.3.2 M inim ally Invasive C A B G
Although OPCAB reduced the complications with the use of CPB, this type 
of surgery is still limited by the requirement for a median sternomony. This may
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adversely affect patients with significant post-operative morbidity and discomfort. It 
is now therefore possible to undergo a minimally invasive approach, which avoids 
median sternotomy.
The first minimally invasive surgery was performed in 1967 by Kolessove, a Rus­
sian surgeon [77], who performed internal thoracic artery grafts to coronary artery 
anastomosis on a beating heart. However, his pioneer work was not appreciated un­
til nearly 30 years later when it was revisited in the 1990’s with improved imaging 
techniques. The procedure is called minimally invasive direct coronary artery bypass 
(MIDCAB). MIDCAB is typically defined as a surgery without median sternotomy 
but with small incisions between the patient’s intercostal space, and its less inva­
siveness leads to a better post-operative function, fewer blood transfusions, a faster 
recovery time, and shorter lengths of hospital stay [78-80]. However, because a sur­
geon has only a limited view of the heart due to the small incisions, longer operating 
and myocardial ischemic times have been observed, as well as target vessel misiden- 
tification may occur.
1.3.3 R obot-assisted  C A B G
Robot-assisted CABG (RA-CABG) is a variation of the minimally invasive ap­
proach. While MIDCAB achieves a direct view of the heart from the incisions 
made, RA-CABG fully depends on the visualization observed thorugh the a three- 
dimensional stereo endoscope. Therefore, RA-CABG is also referred to as, totally 
endoscopic coronary artery bypass (TECAB).
The da Vinci surgical system (Intuitive Surgical Inc., Mountain View, CA), the 
only such system approved by the FDA, is employed in RA-CABG procedures. The 
da Vinci system is composed of two parts: a master console and a slave robot. While 
high-definition three-dimensional video visualization is offered from the endoscope, 
the surgeon is situated in the master console and controls the slave robotic arms re­
motely. At the patient table, three small incisions are made in the patient skin to
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Fig. 1.1: RA-CABG of left internal mammary artery on the left anterior descending 
artery using da Vinci surgical system. Image courtesy of Maria Currie, London, ON
accomodate: the endoscope and the left and right robotic arms (Fig. 1.1). From 
there a high-definition endoscope is inserted into the thoracic cavity via the fifth in­
tercostal space, while the third and seventh intercostals are used for the right and 
left robotic instruments respectively. Under the remote control of the surgeon, micro- 
surgical instruments with 7 degrees-of freedom achieve high-precision, well-controlled 
and wide-ranging movement at its tips. Also, thanks to the robotic system, any 
unintentional movements from the surgeon are filtered.
RA-CABG can be performed either on pump, while the patient is connected to 
the cardiopulmonary bypass, or off-pump, on the beating heart. Although Bonatti et 
al [81, 82] reported that all their patients recovered without any major adverse car­
diac or cerebral events following the on-pump RA-CABG performed on the arrested 
heart, this approach may lead to complications, such as post-perfusion syndrome or 
arrhythmia due to prolonged use of the CPB. To minimize these risks, many groups
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have adopted the off-pump RA-CABG approach [83-86], leading to approximately 
25% increase in its use across North America [87].
Although off-pump RA-CABG is a new technique for revascularization, many 
studies have been conducted to validate its efficacy. Srivastava et al [88] reported 
that early patency of the graft is around 99% while clinical freedom from graft failure 
reached 98.6%. Also, Gao et al [89] concluded that RA-CABG is a safe procedure 
with an excellent early and midterm patency of anastomosis. Moreover, Argenziano 
et al [90] reported that they achieved 91% of overall freedom from reintervention or 
angiographic failure for RA-CABG on the arrested heart, and Falk [91] agreed with 
the procedure’s safeness and efficacy.
As surgeons depend completely on the visualization of the 3D endoscope, the 
experience and expetise is a must to perform a procedure safely. With the same 
reason, they encounter a substantial learning curve. Moreover, although the number 
of RA-CABG procedures are increasing, the cost of the surgical system is a major 
factor preventing many institutions to employ it. Lastly, because of its short history, 
the long term results of this procedure has yet to be validated.
1.4 M otivation
A major limitation of the robot-assisted technique is the need to convert to open- 
chest surgery because of the difficulties associated with the access and manipulation 
of closed-throacic surgery. The conversion rate has been reported to be in the range 
of 15% — 25% [92-94] and it has been primarily caused by the inability to access the 
surgical target with the robotic instruments, lack of adequate workspace inside the 
thoracic cavity and instrument collision.
In an effort to reduce the need for conversion, several groups have relied on ex­
ploiting the pre-operative CT images routinely acquired prior to the procedures. Figl 
et al [95] proposed a method to “highlight” the surgical targets in the endoscopic
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Fig. 1.2: (a) Pre-operative surgical planning based on pre-operative CT image, show­
ing left anterior descending artery (red), robotic arms and intercostals space (yellow 
lines); (b) US images of left lung deflation stage with the aortic valve and mitral valve 
extracted; (c) The shift from left lung deflation (orange) to the thoracic insufflation 
(gray) and their corresponding segmented valvular structures.
display of the da Vinci system by overlaying the pre-operative CT image onto the 
real-time video. Unlike Figl et a l, who used the pre-operative image as an intra­
operative image guidance tool, Trejos et al [96] used the pre-procedural CT image to 
identify the optimal port placement configuration that facilitates access to the targets 
and prevents instrument collision during manipulation. To improve robustness, Falk 
et al suggested a complete cardiac navigation platform that integrates both patient 
and robot modeling and surgical planning, as well as an augmented reality overlay of 
the pre-operative images onto the endoscopic view [97].
While these approaches rely on a surgical plan based on pre-operative data ac­
quired days prior to the procedure, no attempts have been reported that use peri­
operative information to update the pre-operative plan, to better reflect the intra­
operative conditions. In order to ensure adequate space for instrument manipulation, 
the procedure workflow of RA-CABG comprises two “invasive” processes - left lung 
deflation and CO2 thoracic insufflation (see Fig. 1.2). As a result, the intra-operative 
location of the heart and surgical targets may differ significantly from that depicted 
in the pre-operative CT image. Thus, by not taking into account these migration 
patterns, conversion may be required, as the planned access path to the target ves-
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sel may be invalidated by the peri-operative heart displacement. Hartung et al. [98] 
have proposed an image-guided approach which overlays the segmented left anterior 
descending (LAD) artery — a typical surgical target for CABG procedures, onto the 
endoscopic video by registering the pre-operative CT to the intra-operative stereo 
image. Their study, however, was conducted via median sternotomy rather than in 
a minimally invasive fashion, and hence the heart displacement induced via open- 
chest access could exceed that induced by robot assistance. Thus, we propose a novel 
method for acquiring peri-operative images of the heart using tracked ultrasound (US) 
and predict the intra-operative location of the LAD by registering the pre-operative 
CT data to the intra-operative US data. This approach has the potential to provide 
an optimal port placement during pre-operative surgical planning and consequently 
reduce the conversion to conventional CABG.
1.5 T hesis C ontributions
The goal of this project is to improve the pre-operative surgical planning of RA- 
CABG by providing peri-operative migration patterns of the LAD through US-to-CT 
registration. The specific objectives that must be met to achieve this goal are:
• Develop registration techniques which fuse intra-operative US images to pre­
operative CT images.
• Conduct an in vitro validation study, in which clinically observed migration 
patterns were simulated to assess and compare the accuracies of the registrations
• Conduct clinical validation study using offline data from patients who under­
went RA-CABG.
• Measure the shifts of the heart induced by peri-operative interventions.
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1.6 T hesis O utline
This thesis is organized as follows:
Chapter 1 provided as an introduction to the clinical background of coronary 
artery disease to provide a context for the motivation of the work to be presented 
in the remainder of this thesis. The pathophysiology and the treatment of coronary 
artery disease as described, as well as the different types of CABG techniques.
Chapter 2 introduces image-guided surgery and its current status. It presents 
and discusses the registration technique, which is a crucial part of image-guided 
surgery. It also introduces the rigid-body registration algorithms that were devel­
oped as part of this thesis’ work.
C hap ter 3 is a description of the in vitro validation experiments performed on a 
beating heart phantom to assess the accuracy of the registration techniques.
Chapter 4 presents a clinical validation as well as the clinical applications of the 
registration. Offline patient data were employed for the clinical validation following 
simulations. The migration patterns of the heart, which were induced by interventions 
in RA-CABG, were also observed.
C hap ter 5 presents conclusions and explores future directions. A discussion is 
presented on how the pre-operative surgical planning of RA-CABG can be enhanced 
by updating the migration patterns of the heart and how the registration technique 




Since the development of the x-ray by Roentgen in 1895, medical imaging has since 
significantly improved and been extended for other types of imaging such as US, CT, 
magnetic resonance (MR) images, positron emission tomography, and single-photon 
emission computed tomography. Nowadays, many procedures employ more than one 
type of imaging modality and the role of imaging is no longer limited to finding a 
lesion before a procedure, but is actively employed intra-operatively to improve the 
outcome of the procedure, i.e., image-guided surgery. To obtain maximum bene­
fits from multiple modalities, it is important to fuse different modalities effectively. 
Registration is one way to fuse images within a single frame. This chapter will re­
view the current techniques of registration in medical imaging and the mathematical 
explanation of “rigid-body” registration, which was employed in our project.
2.1 Im age R egistration  in surgeries
As explained above, imaging is used to visualize important anatomical features, 
either pre- or intra-operatively. However, each imaging modality has different usages 
during the course of the procedure. Thus it is important to show the changes in 
various anatomical features between different stages of the procedure within the same
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modality, as well as between different imaging modalities. Image registration plays 
a key role in the detection of change between stages by aligning one set of images 
to another. US imaging is commonly used intra-operatively bacause of its unique 
ability to acquire images in real-time, while other modalities such as CT or MR 
images are typically taken in pre-operative stage. However, the lack of detail from 
US requires registration to CT or MR images, which provide more image details 
and anatomical features. Image registration from CT, MR or fluoroscopy to US has 
been reported by many groups such as Huang et al [99] who registered 2D US to 
3D CT to provide high quality details of the beating heart. Also, Gobbi et al [100] 
overlaid intra-operative US images onto a pre-operative MR image in stereotactic 
neurosurgery to gain better visualization during the procedure, while Linte et al [101] 
registered subject-specific models, segmented from MR images, to intra-operative US 
images in order to create a virtual reality environment for image-guided mitral valve 
surgery. Recently, Lang et al [102] registered fluoroscopy to US images to improve 
visualization during percutaneous aortic valve replacement surgery.
Image registration is widely used in medical imaging research, in fields such as 
neurosurgery [103-106], radiotherapy [107, 108] and cardiac surgery [109-111], and 
many different registration algorithms such as rigid-body registration and non-rigid 
registration have been developed to meet the needs of the different cases outlined 
above. Among these different techniques, we focus solely on rigid-body registration 
in this thesis.
2.2 R igid-body R egistration
The rigid-body registration problem can be formally stated as an approximation 
problem. Given two different datasets (usually images or sets of points), rigid-body 
registration aligns them so that important spatial features are matched between the 
datasets by applying a simple transformation. While the datasets can have different
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dimensions depending on images (typically 2D or 3D), rigid-body registration has six 
degrees of freedom (DOF) in three dimensions (3D), which specifies the translation 
and rotation required to align the images. Note that rigid-body registration some­
times implies registration which includes rigid-body, similarity, and affine registration. 
Similarity transformations comprise translation, rotation and anisotropic scaling (9 
DOF), while affine transformation has an additional shearing transformation on top 
of the similarity transformation (12 DOF). In this thesis, “rigid-body” registration is 
defined to be a simple 6 DOF registration. In the following two sections, two different 
rigid-body registration techniques are discussed.
2.2.1 Point-based R egistration
Registration algorithms use different types of constraints. The types of rigid-body 
registration can typically be divided into two classes, landmark-based and intensity- 
based. Given two image datasets, intensity-based registration does not require dataset 
segmentation for feature extraction, but rather uses correlation metrics on the inten­
sity patterns in the datasets to perform the registration. Therefore, it is important to 
know what imaging modalities are being used prior to registration, as intensity-based 
registration employs different voxel measures for registration processes compared to 
point or feature based. Generally speaking, registration can be employed on the same 
modalities (intramodality) or different modalities (intermodality). For intramodality 
registration, the sum of the squared intensity difference can be used as a registration 
quality metrics, while mutual information or normalized mutual information may be 
preferred for intermodality registration.
In point-based registration, on the other hand, it is the identification of homolo­
gous features in each image that is important. Feature extraction can be performed 
manually or automatically, and the points collected are called fiducial markers or 
fiducial points. Once the desired anatomical features have been extracted from the 
datasets, the registration then discards the original datasets and proceeds with just
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the point sets defining the features for further processing. While point-based regis­
tration may be performed in 2D to 3D or 3D to 3D, for the purpose of our discussion, 
point-based registration will refer to 3D to 3D only. Given two equal sized sets of 
points, p, the moving points, and q, the fixed points, point-based registration becomes 
the problem of finding the least squares rigid-body transformation which minimizes 
the Euclidean distance between the two point sets. To achieve this, one computes a 
translation vector, t , and a rotation matrix, R, that minimizes:
R  can be found by minimizing e2 and then computing t = q — i?p.
This least-squares estimation problem has a closed-form solution and so does not 
require an iterative solution method. Horn’s method using unit quaternions [112] and
N
(2.1)
where N  is the number of points.
Pseudo code for the registration process is given below:




(2) Compute the displacement between the centroid and each point in the data set.
P = Pi - P
q = q i - q
(2.4)
(2.5)
(3) The minimization problem becomes:
N
(2.6)
a singular value decomposition (SVD) [113] is commonly used for this procedure (see 
Appendix A).
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2.3 Surface-based R egistration
Surface-based registration is similar to point-based registration in that it also 
requires feature extraction from image datasets. While point-based registration is 
restricted to using homologous points, which are the corresponding points on both 
images that should represent the same ordered features, surface-based registration 
has more freedom in terms of the types of constraints used because surfaces can be 
defined as a simple point set, faceted surface, implicit or parametric surfaces. The 
variety of constraint choices allows this registration to be used widely in image-to- 
image (CT, MR or other modalities), or physical-to-image registration (i.e., bone 
to image). Surface-based registration is employed when the number of homologous 
point pairs is insufficient for robust registration. The skin boundary surface, any 
bone structure or any other surfaces with high contrast are good candidates for this 
registration.
2.3.1 Iterative C losest Point
There are many registration algorithms available for surface-based registration, 
such as Head and Hat or Disparity functions. However, the iterative closest point 
(ICP) algorithm is one of the most widely used algorithms. ICP was first introduced 
by Besl and McKay [114] and finds the best transformation between two datasets 
by reducing the general nonlinear minimization problem to an iterative point-based 
registration problem. While ICP can be used in various representations as described 
above, point sets and triangle sets are the most common representations, since many 
segmentation algorithms in medical imaging extract features in this manner.
Given the source and target datasets (i.e. images), the steps involved in ICP are:
(1) An initial registration (i.e. a simple rigid body registration) is applied to the 
source dataset so that the two datasets align relatively close to each other.
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(2) Place the source dataset into a ¿-dimensional (kD) tree.
(3) Each target point finds its closest Euclidean distance source point from this kD 
tree.
(4) Using these target and closest source point sets, perform point-based registration.
(5) Find the residual from the transformation to describe the quality of the match.
Steps 2 to 4 are repeated until the algorithm satisfies the termination criteria 
based on the difference between two adjacent registration residuals being smaller 
than some threshold (user defined). The initial transformation can be performed in 
many different ways, such as using several landmarks for the registration. As ICP is 
sensitive to the initial registration, it is important to first accurately align the source 
and target datasets before any processing is further done.
2,3.2 R obust S tatistics
A potential problem with using the original ICP algorithm is that its accuracy may 
be compromised when the data contain erroneous measurements, since ICP weighs 
every point equally. However, since the data was obtained by a manual segmentation 
(the features are defined manually rather than computed), it is inevitable that it 
contains some points that are not as accurately aligned as others. Removing outliers 
during the registration process could greatly improve its accuracy and some types of 
robust estimator are widely employed to achieve this.
There are various different types of robust estimators and one way to characterize 
them is to compare the gross-error sensitivity, meaning how well a certain estimator 
responds to various ranges of error.
For example, the least-squares estimator has an unbounded gross-error sensitivity 
since it will include any point, no matter how large the errors are. This estimator,
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therefore, is not suitable for outlier detection. For this reason, the gross-error sensi­
tivity of most robust estimators is bounded, and different estimators have different 
means of setting the bounds on the gross error. The influence function (how outliers 
are weighed) is commonly used to visualize the gross-error sensitivity.
Three influence functions are shown in Fig. 2.1. As the above described, the least- 
square estimator demonstrates a linear behaviour without bound, while Lorenzian’s 
and Tukey’s biweight influence functions start decreasing the influence of outliers at 
a certain point. Given that different functions behave differently, a robust estimator 
should be chosen carefully based on the application.
Once the right estimator has been chosen, it is also important to determine the 
rejection point for a given dataset and a scale parameter is used to determine a proper 
rejection point. A standard scale parameter for a robust estimation (a) is the median 
absolute deviation (MAD), as shown in Equation (2.7) below:
a = c- mediarii {|Xi — mediarij {xj}\} . (2.7)
The constant c is designated for optimizing a value of the estimator to a particular 
distribution. For example, if the distribution is a zero-mean normal distribution, 
constant c could be 1.4826 to cover one standard deviation of the population.
2.3.3 R obust ICP
Our robust ICP algorithm was originally adopted from Ma [115]. The principle of 
robust ICP is to perform weighted ICP, where the weights are determined by a robust 
estimator. To integrate the weights in ICP, Horn’s method is preferred over SVD, 
because using weights in Horn’s method has already been described in his algorithm 
(i.e. Tukey’s biweight), while SVD does not provide any straightforward way to use 
the weights. Therefore, for each iteration of ICP, the scale of the robust estimator 
is computed based on residual errors of the dataset and consequently outliers are 
discriminated against while weights are assigned to the remaining data points. A
26
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Fig. 2.1: Influence function of (a) least-squares error norm, (b) Lorentzian error norm 
and (c) Tukey’s biweight error norm.
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pseudo code for Robust ICP is provided in the Appendix B, which was adopted 
from Ma [115].
2.4 Evaluation
The purpose of registration is to align two different images of anatomical features 
within the same view, to observe the changes between two stages and to enhance the 
detail of the features. Maintz and Viergever [116] recommeneded ways to evaluate 
registration, such as precision, accuracy, robustness, resource requirements, algorithm 
complexity, assumption verification and clinical use. However, this section will focus 
only on the quantitative accuracy of aligning two image datasets as an assessment of 
reliability, and not on patient outcome. As discussed by [117], there are two measures 
used to define accuracy of the registration algorithms:
1. target registration error (TRE) and
2. fiducial registration error (FRE).
2.4.1 Target R egistration  Error
Target registration error is the most important alignment measure when speak­
ing of registration accuracy. The term “target” has been used to differentiate it 
from “fiducials”. As explained in Section 2.2.1, fiducial points are those used for 
registration purposes. They are usually chosen based on their visibility in different 
modalities. As a result, they are usually not clinically relevant anatomical features 
but rather salient points such as bright spots on images, vascular junctions etc. How­
ever, unlike fiducials, targets are anatomical features or regions the surgeon is looking 
for in the procedure or during diagnosis. As a result, TRE is the most meaningful 
of the error measurements. Given that p and q represent target points in the first 
and second image datasets respectively, TRE can be found using T, a transformation
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computed from evaluating a registration:
T R E  = \\T (p )-q \\2. (2.8)
2.4.2 F iducial R egistration  Error
Fiducial registration error is a measurement based on the points which have no 
significant clinical meaning, but are used for registration only. When fiducials are de­
fined either manually or automatically, there may be errors associated with localizing 
them. This type of error is called fiducial localization error (FLE) and because FLE 
always occurs before registration is performed, FLE affects both the FRE and TRE. 
The presence of FLE means that FRE cannot be used as an estimate of TRE because 
it may cause either an underestimation and an overestimation of FRE. Underesti­
mation occurs when a value of FRE is lower than the value of TRE. This happens 
because a registration attempts the best to find the best transformation to match the 
fiducials. When actual fiducials are incorrectly defined in the same manner in one 
image dataset, it will yield low FRE because the registration tries to align fiducials as 
close as possible. However, this will lead TRE to be greater since the error in localiz­
ing fiducials adds onto the TRE. For example, if the FLE on one image dataset is 1 
mm in the x  direction while the FLE on another dataset is 2 mm in the y direction, 
the registration would result in a FRE of 0 but a TRE of 2.2 mm ( \ / l2 +  22 «  2.2) 
because of the FLE (see Fig. 2.2).
Secondly, overestimation occurs when the value of FRE is higher than the value 
of TRE, when the error on each fiducial is not defined in the same manner to each 
other, but with a different magnitude and/or direction. The end result could be that 
TRE is small after the registration but FRE would be larger compared to TRE, which 
concludes that FRE overestimates TRE. For example, half of the fiducials have an 
error of +1 mm in the x  direction while the other half have an error of -1 mm in the 
x  direction. In this case, FRE will yield 1 mm while TRE will continue to be zero
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Fig. 2.2: Schematic of underestimation: (a) Fiducials are localized with FLE of -1 
mm in x  direction on the first image, (b) Fiducials are localized with FLE of 2 mm 
in the y direction on the second image and (c) registration yields 0 mm of FRE while 
2.2 mm of TRE due to underestimation
(see Fig. 2.3). Lastly, Fitzpatrick [118] has shown that TRE and FRE are actually 
uncorrelated mathematically and experimentally via computer simulation. Although 
FRE values are much less than TRE in general, FRE could still be a good measure 
to evaluate the registration results because FRE is easier to compute than TRE and 
measuring FRE could be a good means of validating the quality of the registration.
FRE is typically reported as a root-mean-square (RMS) calculation as follows:
F R E 2 = J 2 \T (P i) -q i\2 . (2.9)
2.5 Sum m ary
As different modalities are being used in an image guided surgery, it is crucial 
to have a good registration between source and target image datasets. This chapter 
explained rigid-body registration, with a focus on landmark based registration. While 
there are many types of rigid-body registrations available, our work focuses on a 
modified ICP algorithm, which is a type of surface-based registration which uses 
Tukey’s biweight statistical estimator. Moreover, we have discussed the evaluation
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Fig. 2.3: Schematic of overestimation: (a) Half of the fiducials are localized with FLE 
of-1 mm in the x direction while others are localized with FRE of 1 mm in x direction 
on the first image, (b) Fiducials are localized with FLE of 0 mm on the second image 
and (c) registration yields 1 mm of FRE while 0 mm of TRE due to overestimation.
measures (TRE and FRE) to assess the accuracy of the registration. The following 
chapters explore how the registration discussed in this chapter may be implemented 





As discussed in the motivation of the project, the intra-operative imaging modality 
(i.e. 2D Trans-esophageal echocardiography) is not able to identify the surgical target 
vessel under the current RA-CABG setting. To bypass this issue, registrations that 
involves the anatomical features as contraints, which are visible on both pre-op CT 
and intra-op Trans-esophageal echocardiography (TEE), were developed. As a initial 
step toward a full validation, we conducted an in vitro study using a realistic heart 
model.
3.2 M aterials and M ethods
3.2.1 C linical Procedure W orkflow
In a typical robot-assisted CABG procedure, a pre-operative CT image of the 
patient is acquired for surgical planning (Stagecr). To ensure sufficient work space 
inside the closed-chest, during the procedure, the patient undergoes several “inter­
ventions” consisting of intubation and anesthesia delivery (Stageo), deflation of the
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left lung (Stagei), and thoracic insufflation (Stage2). To illustrate how pre- and 
intra-operative imaging is used to obtain measurements of the heart migration dur­
ing the RA-CABG procedure, we follow a hypothetical patient through the proposed 
workflow.
3.2.1.1 Image Acquisition
A cardiac-gated CT image of the patient’s thorax depicting the heart at mid­
diastole is acquired as part of a routine pre-operative exam for a patient undergoing 
RA-CABG. Since the images are acquired with contrast enhancement, they provide 
reliable information with regards to the shape and location of the major vessels, 
including the LAD.
During the robot-assisted procedure, 2D TEE is used to acquire images of the 
patient’s heart at each stage of the peri-operative workflow using a Philips SONOS 
7500 scanner (Philips, Andover, MA). While TEE is the standard imaging modality 
for cardiac monitoring during interventions, for this application, the image acquisition 
is spatially tracked using a modified TEE transducer [119]. Surgical tracking technol­
ogy has become indispensable in image-guided interventions, as it allows surgeons to 
identify the position and orientation of the instruments and visualize them relative to 
the anatomy and surgical targets. In spite of the high localization accuracy achieved 
using optical tracking technology [120], this application favours magnetic tracking 
since no direct line-of-sight can be established between the TEE probe inserted in the 
patient’s esophagus and an optical tracking camera mounted overhead. As a result, 
the NDI Aurora (Northen Digital Inc., Waterloo, ON, Canada) magnetic tracking 
system is employed; the TEE transducer is tracked via a 6 DOF sensor embedded 
inside the casing of the probe, while another 6 DOF single disc marker is attached 
to the patient as reference. Using the magnetically tracked probe, US images of the 
patient’s heart are acquired from different views to depict several features of interest 
at each peri-operative workflow stage.
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St 1: Dual-lung vent. St 2: Single-lung vent. St 3: Chest insufflation
Fig. 3.1: Graphical representations of the peri-operative heart shift during RA-CABG 
procedure: (a) after intubation and anaesthesia (red) (b) after left lung deflation 
(green), and (c) after chest insufflation with CO2 (blue)
3.2.2 E stim ating Peri-operative Heart M igration
In a previous investigation [109], the migration of the heart was studied in four 
patients using a feature-based registration technique that relied on the mitral and 
aortic valve annuli to describe the location of the heart. Preliminary data have 
shown that the heart undergoes substantial displacement following lung deflation 
and thoracic insufflation, resulting in changes in position on the order of 25 — 35 mm 
between the pre- and intra-operative conditions (Fig. 3.1).
We also have observed from the same study that the morphology of the valvular 
structures (i.e. length of short and long axis, valve annulus perimeter and inter- 
valvular distance) remains relatively unchanged throughout the workflow, despite 
considerable displacement of the heart. Based on the suggested conclusions that 
no significant non-rigid deformations occurred, our aim is to improve the currently- 
employed feature-based rigid registration by adding additional constraints near the 
base and apex of the heart, to yield optimal alignment along the surgical target - the 
LAD coronary vessel.
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3.2.2.1 Predicting Target Vessel Location
Since the LAD can only be identified in the pre-operative CT image and not in 
the peri-operative US images, its intra-operative location must be inferred from the 
pre-operative data. Therefore, four anatomically relevant features that can be easily 
identified from both CT and US are used to assist in the pre- to intra-operative 
registration: the left coronary ostium (LCO), the mitral valve annulus (MVA), the 
aortic valve annulus (AVA) and the left ventricular apex (LVAp). The LAD begins 
at the LCO and typically runs toward the LVAp, while the MVA and the AVA are 
located on either side of the staring point of the LAD. The MVA and the LVAp are 
captured from a mid-esophageal-4-chamber-view at 20° increments from 0° to 180°, 
while the AVA and the LCO are viewed from five long axis view images with 10° 
increments, and one short axis view of the aorta at 30°. These features are manually 
defined by an expert anesthetist on both CT and US images using a custom-developed 
feature extraction tool: the MVA and the AVA are delineated as rings while the LCO 
is identified as a point, and the LVAp as a paraboloid. Lastly, the path of the LAD 
is also traced on the pre-operative CT dataset.
3.2.2.2 Pre- to Intra-operative Feature-based Registration
Two rigid-body registration algorithms that employ the four anatomical features 
were investigated in this work: the first treats the extracted features as single land­
marks with empirically-assigned weighting factors, while the second relies on a mod­
ified ICP approach to align the four features in the homologous datasets.
Weighted Landmark-based Registration: After the four anatomical features 
— the LCO, MVA, AVA and LVAp — are identified in the pre- and peri-operative 
datasets, as a means to reduce the variability associated with their manual segmenta­
tion, the features are treated as single landmarks, as follows: the LCO, the centroids 
of the mitral (MVA) and aortic (AVA) valve annuli, and the vertex (i.e.global mini-
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mum) of the LVAp segmented surface. Moreover, treating these features as landmarks 
had the added benefit of reducing processing time.
Simple landmark-based registration was performed using the four landmarks, fol­
lowed by the minimization of the Euclidean distance between the LCO and LVAp 
using downhill simplex optimization [121]; these two features — LCO and LVAp, 
were selected as the primary constraints for the registration given they bound the 
superior and inferior ends of the LAD.
Robust ICP-based Registration: The second registration technique employed 
the complete geometry of the anatomical features consisting of the LCO, two 3D 
closed curves describing the MVA and AVA, and a parabolic structure defining the 
“cap” of the left ventricular apex. For better accuracy, a virtual surface model of the 
left ventricle apex was generated from the pre-operative CT dataset along with the 
intra-operative features.
The robust ICP-based approach is an extension of the traditional ICP algorithm 
employing Horn’s method to compute the registration transform [112, 114], with the 
addition of a robust estimation technique [115]. The purpose of the robust estimator 
is to reduce the effect which outliers within the datasets — in this case resulting from 
inconsistencies in the extracted features due to manual segmentation — may have on 
the overall registration. Based on different robust estimators which were discussed in 
2.3.2, Tukey’s biweight is the best option for our project as it is considered to provide 
reasonable performance across a wide range of three-dimensional data [115]. The 
robust estimator assigns weights to each point based on the residual error between 
the registered source and target points after each iteration, and it also effectively 
discriminates against outliers whose residual error exceed a certain value by assigning 
them zero weights [122]. The estimated weights are then used in Horn’s method to 
compute the transform.
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3.2.3 In vitro E xperim ental V alidation
3.2.3.1 Experimental Apparatus
The in vitro study was conducted on a heart phantom (The Chamberlain group, 
Great Barrington, MA, USA) and the apparatus was set up in a similar configuration 
to that observed in the operating room (OR). Heart migration patterns similar to 
those observed in our preliminary clinical study [109], were simulated in vitro by 
changing the position and orientation of the phantom to mimic the observed peri­
operative displacements. Sixteen CT-visible fiducials were attached to the surface of 
the heart phantom: ten were used to perform the physical-to-image space registration 
and the remaining six were used to outline the LAD path (Fig. 3.2a). The position 
of the heart phantom was tracked throughout the experiment using a 6-DOF NDI 
magnetic sensor attached to the phantom, while another 6 DOF single disc marker 
was rigidly attached to the table to serve as global reference.
3.2.3.2 Image Acquisition
A pre-operative CT image of the phantom was acquired on a GE 64-slice Light- 
Speed VCT scanner with the voxel size of 0.49 mm x 0.49 mm x 0.63 mm (General 
Electric, Milwaukee, WI, USA) and a virtual model of the phantom was generated 
using automatic segmentation tools available in ITK [123].
Peri-operative US images of the phantom were acquired using the magnetically 
tracked TEE probe described in 3.2.1. The position and orientation of the phantom 
was changed twice to simulate the lung deflation and thoracic insufflation; the four 
features - LCO, MVA, AVA and LVAp - were imaged three times at each of the three 
workflow stages, and also the entire protocol was repeated three times to minimize 
human error.
Once all the images were collected, the features were extracted using a custom- 
developed segmentation tool. All features were defined in the same 3D coordinate
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Fig. 3.2: (a) An heart phantom image showing the LAD path; and (b) Peri-operative 
US image acquisition protocol showing imaging of the apex and coronary ostia using 
incrementally tracked 2D US images.
space: the LCO was identified as a single marker, the MVA and AVA were segmented 
as 3D “rings”, and the LVAp was segmented by manually tracking the epicardial 
contours of the apex in each of the 2D US images (Fig. 3.2). Lastly, the location 
of the LAD vessel was also delineated on the pre-operative CT image using the six 
fiducial markers, while its peri-operative location would be inferred using the proposed 
registrations techniques.
3.2.3.3 Computing LAD Target Registration Error
The six fiducials that marked the LAD path were used to assess the TRE between 
the predicted LAD location and its gold-standard location at each stage in the work- 
flow. The gold-standard locations of the LAD fiducials were determined by recording 
their positions at each stage using a magnetically tracked pointer. The predicted 
LAD location was identified by applying the registration transform computed from
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Table 3.1: LAD TRE: Mean ±  SD and RMS (mm) in in vitro study
Stages Robust ICP-based Weighted landmark-based
to CT Mean ±  SD RMS Mean ±  SD RMS
Stage0 2.0 ±  0.7 2.1 3.3 ±  1.7 3.7
Stagei 3.0 ±  1.2 3.3 4.1 ±  2.1 4.6
Stage2 2.5 ±  0.8 2.6 4.7 ±  2.4 5.3
Overall 2.4 ±  1.0 2.6 4.0 ±  2.2 4.6
the registrations described in 3.2.2.2 to the pre-operative LAD fiducials.
3.3 R esu lts
In this experiment, three peri-operative RA-CABG procedure workflows were sim­
ulated. For each of these nine poses, we acquired three sets of tracked US images, 
defined the features of interest and used the two different proposed registration al­
gorithms (weighted landmark-based registration and robust ICP-based registration) 
to predict the intra-operative LAD vessel location based on its pre-operative loca­
tion. The TRE between the actual locations of the LAD target fiducials (the ground 
truth) and their predicted locations from the registration were computed for each of 
the stages (Stageo, Stagei and Stage2) in the pre-operative CT images (Fig. 3.3). 
Table 3.1 summarizes the overall TREs computed from two registrations between 
the three stages. We can see the robust ICP-based registration outperforms weighted 
landmark-based registration at all stages. Also, for a visual interpretation of the 
LAD TRE, Fig. 3.4 shows the virtual model of the heart phantom along with the 
gold-standard and predicted LAD paths of robust ICP-based and landmark-based 
registration.
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Fig. 3.3: Graphical representation of the target registration errors of the two reg­
istration techniques (robust ICP-based and Weighted Landmark-based) from peri­
operative stages (Stageo, Stagei and Stage2) to pre-operative stage (Stagecr)-
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Fig. 3.4: (a) Pre-operative heart phantom model showing the gold-standard LAD 
(white); (b) Visual display of the LAD TRE (purple) from landmark-based, (c) and 
robust ICP-based approach
Table 3.2: RMS Feature Localization Error (mm)
Feature Stage0 Stagei Stage2
LVAp 2.3 4.7 4.0
AVA 1.4 1.3 1.2
MVA 0.6 1.9 1.5
CO 1.1 4.0 2.1
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3.4 D iscussion
This work constitutes the first steps towards optimizing pre-operative planning for 
RA-CABG procedures. Motivated by a recent clinical study that revealed substantial 
migration of the heart during the peri-operative procedure workflow, our goal is to 
predict the intra-operative location of the target vessel, to provide the surgeon with 
an optimized surgical plan that better reflects the intra-operative stage. As a bridge 
to the in vivo validation, considering the limitations arising due to poor visualization 
and identification of the LAD coronary vessel in clinical US images, the in vitro 
phantom study was performed to assess the accuracy of two proposed registrations: 
weighted landmark-based registration and robust ICP-based registration.
Both registration techniques were used to predict the peri-operative LAD location 
at each pose in the workflow; according to the TRE computed along the LAD, the 
robust ICP-based approach outperformed the landmark-based approach, leading to 
an overall RMS TRE of 2.6 mm versus 4.6 mm, respectively (see Table 3.1). From 
the results, the trend of higher errors closer to the apical end of the LAD was observed 
in the weighted landmark-based registration while the robust ICP-based registration 
stays relatively consist ant. This observation is mainly due to the nature of the reg­
istration as the weighted landmark-based approach was limited to the use of four 
landmarks for registration, while the robust approach used the complete geometry 
of the features of interest for registration. The RMS FRE between the predicted 
location of four features and the gold-standard location from CT was computed, and 
Table 3.2 includes a summary of the RMS localization error assoicated with the 
identification of each of the four features used to drive the weighted landmark-based 
registration: LCO, LVAp, MVA and AVA. As observed, the point-based localization 
of the LVAp and the LCO was consistently challenging, mainly due to the 2D na­
ture of the US images used to identify a 3D structure and the development of the 
robust ICP-based registration minimized the inconsistency of the point localization
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very well.
Nevertheless, considering that the anastomosis is performed two thirds of the way 
from the left coronary ostium toward the apex, the RMS TRE on point 5 were 2.7 
mm and 4.5 mm for the robust ICP-based and the weighted landmark-based approach 
respectively. While the clinically tolerable error is on the order of 10-15 mm, the 
accuracy provided by the proposed techniques is well within the allowable boundaries 
in the in vitro experimental setting.
3.5 C onclusions
Driven by the clinical motivation to improve the pre-operative planning of RA- 
CABG procedures, here we have proposed and evaluated two registration techniques 
used to predict the intra-operative target vessel locations. Our techniques were val­
idated in an in vitro study simulating the clinically-observed RA-CABG procedure 
workflow. The robust ICP-based registration yielded a 2.6 mm RMS TRE while the 
weighted landmark-based registration yielded 4.6 mm, suggesting that the use of the 
full extent of the selected features led to a better accuracy and consistancy in predict­
ing the LAD location. As the validation is limited to the in vitro study, our technique 
is needed to be evaluated in more clinical setting in order to strengthen its validity 
to be used clinically.
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Chapter 4
Clinical Application and Validation
4.1 Introduction
Although the in vitro study provided a good evaluation of the accuracy of the 
registration algorithm, the apparatus was still deemed inadequate in ensuring that 
the study fully simulated an actual RA-CABG. Therefore, there was a need to perform 
another validation study in a clinical setting. This chapter presents a validation study 
based on the offline patient data which were acquired from RA-CABG procedure.
4.2 M aterials and M ethods
As a follow-up of the in vitro validation, a clinical validation was conducted for 
further assessment of the registration. Although there is a limitation that the target 
vessel is not identifiable in US images, in vivo animal experiments involve complex 
interventions such as lung deflation and chest insufflation which might cause prema­
ture loss of the subject prior to the end of the procedure. Therefore, a validation 
study was conducted using offline data acquired from four patients who had under­
gone RA-CABG and the Monte Carlo simulation method was used to estimate the 
maximum TRE at the LAD.
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4.2.1 Im age A cquisition
For each patient, a pre-operative CT and three-stage peri-operative US images 
were acquired as described in 3.2.1.1. A pre-operative CT was acquired prior to the 
RA-CABG surgery as a routine of the patient care as well as for the pre-operative 
surgical planning purpose. During the surgery, three different interventions to the 
patients have been made to ensure an adequate workspace inside the chest cavity — 
Stageo - after intubation and anaesthesia, Stagei - after left lung deflation, Stage2 
- after chest insufflation. A magnetically tracked TEE was employed to acquire the 
anatomical features of the heart at each stage of the interventions. Following image 
acquisition, the four anatomical features were extracted by an expert anaesthetist, 
while LAD was segmented only from CT image. Like the feature extraction in the 
in vitro study, the AVA and the MVA were delineated as “ring” while the LCO was 
delineated as a single point. The apical region was extracted as a paraboloid shape 
which consists of a cloud of the points. Peri-operative features at each stage were 
registered to the pre-operative stage by robust ICP-based registration, which was 
shown to be superior to the landmark-based registration approach.
4.2.2 A ssessing Target V essel Location
For the in vitro study, the accuracy of the proposed registration algorithms in 
predicting the intra-operative LAD vessel location was assessed as the TRE computed 
along the LAD. However, since the gold-standard location of the LAD could not be 
identified from the US images, we resorted to computing the FRE of the features of 
interest and conducting a series of simulations to estimate the TRE at the LAD based 
on the FRE computed above.
Given that the LAD branches off at the left coronary ostium and toward the apex 
of the heart, in the simulation study, the displacement of the LAD was constrained by 
the displacement of these two features. As the FRE of these features were computed,
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the maximum TRE at the LAD can be estimated and assessed against the clinically 
tolerable error (10-15 mm).
4.2.2.1 Simulation Study
A simulation study was conducted using the Monte Carlo method. The shape of 
the LAD was delineated from each patient’s CT data and the vessel was defined as 
14 sequential points (Fig. 4.1a). For peri- to pre-operative stage registration, the 
computed maximum FRE of the LCO and LVAp was used as boundary conditions for 
the simulations. The displacement for the superior end of the LAD (closely located to 
the LCO) was bounded by the maximum FRE of the LCO, while the displacement for 
the inferior end of the LAD (closest to the LVAp) was constrained by the maximum 
FRE of LVAp. The peri-operative migration patterns of the LAD were modeled 
as a rigid-body transformations consisting of a translation and rotation component. 
Since the purpose of this study was to estimate the “maximum” TRE at the LAD, 
the translation was randomly generated, while ensuring both ends of the LAD were 
inelastically constrained at the maximum boundaries set by the FRE at the LCO 
and LVAp. Considering the curvature of the LAD across the surface of the heart, 
the rotation component was approximated as a rotation about an axis defined by 
the superior and inferior ends of the LAD with a ramdonly generated angle within a 
range of 30 degrees (Fig. 4.1b).
4.2.3  M easuring C hanges in H eart Position
Following the clinical validation, the migration patterns of the heart during RA- 
CABG were measured. As the LAD is not visible on intra-operative US images, it is 
not feasible to measure the shift of the LAD directly. Therefore, with the assumption 
that the heart does not deform significantly during the RA-CABG procedure and the 




Fig. 4.1: (a) LAD extracted from patients CT data (b) LAD with the axes of rotation, 
be a good estimate of that of the LAD.
Prior to the registration, three stages of intra-operative US images as well as pre­
operative CT images were acquired. US images are then transferred into the CT 
image space by aligning homologous features identified during the first peri-operative 
dataset (Stageo) and the pre-operative dataset (Stagecr). These two stages are physi­
ologically equivalent, considering the same patient position and dual-lung ventilation, 
and therefore minimal anatomical variations are expected between them. As a re­
sult, heart displacement induced by the interventions can be measured with respect 
to the principal body axes in the CT coordinate system. The robust ICP-based 
registration was employed to corresponding source and target images to estimate the 
displacements of the heart at each stage (Stagei and Stage2) from its original location 
(Stageo).
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Table 4.1: Maximum FRE of four features (mm) — AVA, MVA, LCO, LVAp — 
employed in clinical validation
Stages to CT Stage0 Stagei Stage2
LCO 1.6 3.1 0.6
MVA 4.3 5.6 1.7
AVA 3.2 6.0 1.6
LVAp 3.7 5.1 1.1
4.3 R esu lts
4.3.1 C linical Validation R esult
We conducted a clinical validation based on the offline patients data to validate 
the proposed registration in a more clinically representative fashion. Pre-operative 
CT and peri-operative US images of four patients undergoing RA-CABG were ac­
quired and the AVA, MVA, LCO and LVAp were extracted. The robust ICP-based 
registration was employed to register the peri-operative stages to their pre-operative 
couterpart. Table 4.1 summarizes the overall FRE of the features employed in the 
registration.
Moreover, the results of simulation study are shown in Fig. 4.2. The simulations 
were conducted using the Monte Carlo method and were used to estimate the TRE 
at the LAD following the peri- to pre-operative registration, using the maximum 
FRE of LCO and LVAp respectively. A total of 10,000 runs was conducted for each 
simulation.
4.3.2  R esult o f M easuring H eart Shift
The result is based from six patients who underwent RA-CABG procedure. Ta­
ble 4.2 showed the magnitude of the displacement of the heart during interventions 
— Stage0 - after intubation, Stagei - after left lung deflation, Stage2 - after chest 
insufflation, with respect to the principal body axes in the CT coordinate system. 
Also, Fig. 4.3 gave the graphical representation of these changes.
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Fig. 4.2: Estimated RMS TRE of the LAD from Monte Carlo simulations which were 
conducted for each peri-operative stage
Table 4.2: Displacement of the heart with respect to the principal body axes in the 
CT coordinate system for Stageo to Stagei, Stageo to Stage2, Stagei to Stage2 (mm)
Workflow Stage0 to Stage! Stage! to Stage2 Stage0 to Stage2
Left/Right 14.3 -4.4 12.8
Anterior/Posterior -1.4 9.3 11.9
Superior/ Inferior 0.4 -6.4 1.3
overall 14.4 12.1 17.5
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Fig. 4.3: Graphical representations of the peri-operative heart shift during RA-CABG 
procedure: (a) after intubation and anaesthesia (red) (b) after left lung deflation 
(purple), and (c) after chest insufflation with CO2 (green)
4.4 D iscussion
Although the in vitro study showed that the robust ICP-based registration yields 
a reasonable peri- to pre-operative registration accuracy, its performance still needs to 
be evaluated in a more clinically relevant scenario. As a result, patient data acquired 
during four RA-CABG patients were used for another validation study. The major 
limitation of clinical data is that the target vessel cannot be identified due to the poor 
image quality of the peri-operative US images, which in turn impedes the estimation 
of the TRE between the predicted and true target vessel. To bypass this issue, a 
simple Monte-Carlo method simulation was conducted. The LAD is anatomically 
bounded by the LCO at its superior end and the LVAp at its inferior end. Since 
the FRE of these features can be estimated from the registration, these values were 
used to constrain the maximum displacement of the LAD at its two ends during 
the simulation. For each peri-operative stage, the maximum TRE of the LAD was 
estimated through the simulation which is shown in Fig. 4.2. Considering the typical 
anastomosis site is located two thirds of the way along the LAD from its superior end,
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the maximum TRE achieved at this site was 4.1, 4.9, and 3.4 mm for Stageo, Stagei 
and Stage2 , respectively. Recalling that the purpose of the simulation study was to 
examine whether the TRE of the LAD exceeded the given clinical tolerance (10 - 
15 mm), these results confirmed that the robust ICP-based registration provide an 
adaquate performance in registering the peri- to pre-operative dataset, yielding a less 
than 5 mm clinical registration accuracy.
Recalling that the conversion from RA-CABG to conventional CABG might be 
caused by an inaccessible target vessel due to inappropriate port placement, it is 
important for the success of the procedure to correctly estimate the intra-operative 
location of the heart. Since there has not been any literature reported related to the 
migration patterns of the heart during RA-CABG, our preliminary results provide 
a glimpse of intra-operative heart motion detection which needs to be further inves­
tigated. The displacements of the heart were observed in terms of principal body 
axis from the starting location (Stageo) to stages after each interventions (Stagei and 
Stage2) as shown in Table 4.2. A big shift, 14.3 mm, to the left was observed from 
Stage0 to Stagei because of the collapse of left lung deflation. Once the chest is in­
sufflated with CO2, the heart was shifted 9.3 mm to anterior, 4.4 mm to right and 6.4 
mm to inferior in 3D space. Thus, the overall displacements from Stageo to Stagei 
and Stage2 were measured as 14.4 mm and 17.5 mm respectively. Although this is a 
preliminary result from six patients, the overall displacements could be noteworthy 
because it showed that the heart could be shifted more than one intercostal space 
during peri-operative interventions, which might impact on the selection of the port 
placement based solely on the pre-operative CT. Therefore, it may assist in selecting 
an appropriate port placement if the estimatation of the heart shift could be updated 
into the pre-operative surgical planning.
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4.5 C onclusions
This chapter evaluated the system which registers intra-operative US images into 
pre-operative CT images using the robust ICP-based algorithm as well as Monte Carlo 
simulations in a clinical validation. The results demonstrated a maximum estimated 
TRE within 5.0 mm at the site of anastomosis, which is within the clinically allowable 
error for the intended application. Moreover, they document the migration patterns 
of the heart, induced by left lung deflation and chest insufflation during the procedure 
with displacements of 14.4 mm and 17.5 mm from the starting position to position 
after left lung deflation and chest insufflation, respectively.
Although the system satisfies clinical needs, limitations remain which need to 
be overcome in order for this system to be implemented in the actual RA-CABG 
procedures. These will be discussed in the next chapter. Nevertheless, the work 
presented in this chapter is a step forward towards port placement optimization in 
RA-CABG procedures and may eventually lead to a reduction in the number of 
conversions to conventional open thoracic surgery for RA-CABG procedures.
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Chapter 5
Conclusions and Future Research
In the sections below we sumarize the thesis contributions, give conclusions and 
point to future research possibilities.
5.1 C ontributions
Much research has been conducted to overcome a chief limitation of off-pump RA- 
CABG, which is the conversion to median sternotomy. However, most of this work 
has tried to solve the problem at the pre-operative stage with the pre-operative CT 
scan, thus not taking into account any peri-operative changes of the heart. Because 
the patient undergoes two interventions, left lung deflation and subsequent chest 
insufflation, to ensure an adaquate space inside the thoracic cavity peri-operatively, 
the peri-operative shifts of the heart should be monitored and be taken into account 
during pre-operative surgical planning.
The work presented in this thesis contributes to the first step towards investigating 
the peri-operative motions of the heart during off-pump RA-CABG procedure. Mag­
netically tracked TEE was employed to acquire images of the heart peri-operatively 
while CT was acquired pre-operatively. The typical target vessel for off-pump RA- 
CABG is the LAD but identification of this target vessel using TEE often failed due
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to the limited depth penetration of TEE probe. Therefore, registrations using four 
anatomical features, i.e. the weighted landmark-based and the robust ICP-based reg­
istrations, were developed to register peri-operative stage images into pre-operative 
stage images. These algorithms enable the displacement of the target vessel or heart 
to be visualized at each intervention during the RA-CABG procedure. To evaluate 
the registrations, an in vitro as well as clinical validations were conducted. In the in 
vitro study, the beating heart phantom with six fiducals that trace the path of the 
LAD was employed while the offline data from patients who underwent off-pump RA- 
CABG were used in the clinical validation. Bearing in mind that the peri-operative 
location of the target vessel cannot be found using current imaging modalities, sim­
ulations were run to deduce the maximum TRE of the LAD following the clinical 
validation.
Since two validation studies yielded positive results, the displacements of the heart 
at each intervention were estimated. These results show that the heart migrated more 
than one intercostal space for both interventions and suggest that this peri-operative 
shift of the heart should not be ignored during the pre-operative planning stage but 
rather should be adapted in order to achieve a better procedural outcome.
5.2 Future D irection
In the subsections below we describe some avenues for future work.
5.2.1 M easuring heart deform ation
The project described in this thesis has been conducted based on the assump­
tion that the heart does not deform significantly during the procedure with Linte et 
al. [109] reporting that the valvular structures of the heart did not deform much dur­
ing off-pump RA-CABG. It still, however, raises questions both from clinicians and 
researchers about the degree of deformation of the whole heart during the procedure,
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Fig. 5.1: Standard 2D view and 3D rendered view of the heart using Philips real time 
3D TEE transducer and iE33 scanner
yet it has not been reported in any studies.
To examine the peri-operative deformation of the heart, the only available imaging 
modality currently used in the OR is the intra-operative TEE. However, the probe 
employed in our project was limited with its 2D dimensionality, therefore the wall 
of the left ventricle was not displayed well, which is a crucial landmark in order to 
see the deformation. Since iE33 ultrasound (Philips, Andover, MA) provides a 3D 
visualization, it can be used to acquire the images of the heart at each stage of the 
intervention in RA-CABG (Fig. 5.1).
Once the degree of deformation is measured, it can then be integrated with the 
registration to compute a more accurate displacement of the target vessel during 
off-pump RA-CABG.
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5.2.2 U p d ate m igration patterns o f th e heart into th e pre­
operative surgical planning
From a broader perspective, this work is aimed at improving surgical planning, 
as well as reducing the conversion to conventional open thoracic surgery by better 
predicting the intra-operative location of the LAD during the pre-operative planning 
stage, so that an optimal port placement can be identified. Since the intra-operative 
locations of the LAD should be updated in the pre-operative stage, the TEE cannot 
be used to find its locations and they have to be “predicted” based on the pre­
operative CT. The prediction of the location of the LAD could be accomplished 
using a statistical atlas. An atlas is a set of CT images that incorporates different 
information. In our case, an atlas consists of CT images of patients who underwent 
the RA-CABG procedures to contain the heart migration patterns and intra-operative 
LAD locations. Since the migration pattern would be different because of the sex, 
shape of rib cage or weight, it is important to select an appropriate subset of CT 
images from the atlas for the best results. Therefore, when a new patient undergoes 
the RA-CABG procedure, the CT images of the patient are acquired so as to select 
the right subset of CT according to a specific classification from CT atlas, similar to 
the one employed by Aljabar et al [124].
Once a patient specific subset is constructed, the intra-operative surgical target 
location can be “predicted” by registering this subset of the atlas to the patient’s CT 
scan.
5.2.3 R eal-tim e update o f th e location  o f th e target vessel
Another way to find the optimal port placement in a RA-CABG procedure is to 
provide a real-time update of the location of the target vessel. However, under the 
current protocol of RA-CABG, the US image acquisition at each pose in the workflow 
is conducted during the procedure, while all feature identification and registration is
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performed off-line. Although registration can be performed in nearly real-time, the 
major drawback is feature extraction, which takes several minutes to complete, leading 
to difficulties in segmenting the required features in real time during a procedure. To 
perform real-time registration, automated feature segmentation is necessary and our 
lab is currently working on the development of automatic segmentation techniques 
for the left ventricle and valvular structures. When accurate registration is followed 
by the ability to perform automatic segmentation in real-time, the updated location 
of the target vessel can be fused into the 3D stereo endoscopic camera in the da Vinci 
surgical system to find an optimal port placement.
5.2.4 E xtension  to  other typ es o f surgery
The techniques presented in this thesis could be employed in other types of min­
imally invasive cardiac surgeries. Minimally invasive mitral valve repair and atrial 
septal defect repair are potential procedures in which this technique could be used. 
While off-pump RA-CABG has two interventions, such as left lung deflation and 
chest insufflation, mitral valve repair and atrial septal defect repair require only lung 
deflation (mitral valve repair - left lung, atrial septal defect repair - right lung). The 
target feature for mitral valve repair is the mitral valve annulus, while the septum 
should be identified for atrial septal defect repair. Since those features are already 
identified as anatomical features in our technique or can be easily identified, the pro­
posed technique can be implemented into these two cardiac surgeries to provide an 
updated intra-operative location of the surgical target for the surgeon, to achieve a 
better procedural outcome.
5.3 C onclusion
Since the first successful revascularization surgery was performed in 1957, CABG 
has evolved to improve the efficacy, as well as the safety of the procedure. RA-
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CABG is a very recent technology which minimizes the invasiveness of CABG and 
reduces the patient’s discomfort during the procedure in addition to length of hospital 
stay. Because this technology is new and still results in a substantial conversion to 
conventional open-thoracic CABG, more research must be conducted in order to adopt 
RA-CABG as a primary treatment option for patients who need revascularization 
surgery. We hope that the work described in this thesis may contribute to improving 
the outcome of the RA-CABG procedure.
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Appendix A
Solutions for least-square 
estimation problem
A .l  Singular value decom position
Algorithm 1 SVD solution 
1: H  = sum of p q
2: U A V T  is the SVD of H
Z: X  =  V U T
4: if determinant of X  — 1 then 
5: R  = X
6: end if
A .2 H orn’s m ethod  using unit quaternions
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Algorithm 2 Horn’s method using unit quaternions
W
2: Where
+ S y y  + S y z  — S z y S z x  — S x z S x y  — S y z
S y z  — S z y S x x  — S y y  — S z z S x y  + S y x S z x  + S x z
S z x  — S x z S x y  +  S y x S y y  — S x x  -  S z z S y z  + S z y
S x y  — S y x S z x  +  S x z S y z  +  S z y S z z  — S x x  — S y y




S y y  =  sum(p(W)i«,2))
8: S y z  =  sum(p(ii2)9(i,3))
S z x  =  sum(p(i>3)9(i>1))
10: S z y  =  sum(p(ii3)(j(ij2))
S z z  =  sum(p(ji3)5(<j3))
12: V =  eigenvectors of W
m  =  eigenvector corresponding to maximum eigenvalue 
14: if the largest value of m  < 0 then  
m  =  m  * — 1 
16: end if
R
m \ + 7712 rrio — m 2 (m27773 +  77127774)
2 (77727773 — 77717774) 777̂ + 7773 — 7772 — m 4
2 ( t7727774 +  777x7773) 2(77737774 — 777i 7772)
2(77727774 — 777x7773) 
2(77737774 +  777i 7772 )
777i +  7774 Tile Til'.
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Appendix B
Pseudo code for Robust ICP
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Algorithm 3 Robust ICP using Tukey’s biweight 
P =  source points
Q = target points
3: S =  scale
{zi} = set of residual errors between P and X 
Pold OO
6- Pnew =  P i^i)
while |pnew ~  Poid\ > tolerance do 
C =  med{£j} * 1.4826 
9: if \zi\ < med{^} then
Wi (z) = [l -  (z/ (c +  m ed \zi\)f]2 
else
12: Wi (z) = 0
end if
use P, A, {wi} and Horn’s method to find a new R  and t 
15: newP =  R  (P) + t
{z^  = set of residual errors between newP and X
Pold Pnew
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